



**COMPANY**

Country	Switzerland
Number of Employees	80'100
Web	www.roche.com

**Share**

Market cap (mil)	145'219
Currency	CHF
High 52 week	191.3
Low 52 week	122.8
Last Price	167.3

**Key Data**                      **2008**                      **2009E**

Sales (mil)	45'617	49'356
EPS	10.43	11.66
P/E Ratio	18.86	14.35

Source: Bloomberg / September 01, 2009

**Sales in**

Alcohol	No
Armaments	No
Firearms	No
Tobacco	No
Gambling	No

Source: EIRIS, SAM Research

**COMPANY DESCRIPTION**

Roche Holding AG is a Switzerland-based pharmaceutical and diagnostics company. Roche Pharmaceuticals is represented in over 150 countries and is a majority shareholder of Chugai, Japan. The company provides differentiated medicines for cancers, viral infections, metabolic and central nervous system disorders and inflammatory diseases. It also develops and markets in-vitro diagnostic instruments and test kits for disease detection and monitoring. Roche's ambition is to be the leading innovation-driven pharmaceuticals/biotechnology company world-wide. It has major research facilities in Europe, USA, Japan and since recently, China. In early 2009, Roche acquired the remaining shares of Genentech it did not own to consolidate its US operations and its global R&D capabilities. On the diagnostics side, the company acquired Ventana Medical Systems and 454 Life Sciences in 2008 to access future growth segments.

**SUSTAINABILITY PERFORMANCE**


Roche Holding AG is the sustainability leader in the pharmaceutical sector for the year 2009. Sustainability is embedded in the core operations of the company and its efforts are illustrated in its performance on all the three dimensions. The company has clearly outlined the depth and breadth of environmental activities and has set ambitious targets for reducing energy consumption and greenhouse gas emission. The company has engaged itself in various programmes such as offering reduced tiered pricing for drugs and facilitating employees to contribute in health related projects in under developed countries. Talented and creative workforce forms the key building block of this innovation oriented sector. To meet this challenge, the company has created various touch points where the employees can share their ideas for improvement and also focus on innovation development programmes e.g. intranet site to facilitate best practices sharing across the group.

**SUSTAINABILITY SCORES**


**Total Score**




**Economic Dimension**



**Environmental Dimension**



**Social Dimension**



■ DJSI sector average on a global basis  
■ Roche Holding AG  
■ Best company on a global basis within DJSI sector



For information on assessment criteria, visit [www.sustainability-indexes.com](http://www.sustainability-indexes.com)

«Corporate Sustainability is a business approach to create long term shareholder value by embracing opportunities and managing risks deriving from economic, environmental and social developments.»


### INDUSTRY DRIVING FORCES

The pharmaceutical sector is a research-driven sector, which heavily depends on the development of new drugs with high top-line sales potential. Rising costs in R&D and weak drug pipelines despite heavy investments are a major challenge for the sector. To maintain profitability and generate higher returns, licensing and acquisitions along with better prioritised spending and more structured decision making, is necessary for the companies. State deficits have led to lower healthcare budgets and put pressure on the pricing of drugs and fuel the discussion about the overall economic value of the products. Access to drugs, novelty character of drugs, and research into diseases with little commercial potential and global patent protection, complying with regulatory regime are other issues for that the sector needs to address. Bio-ethics, drug testing, pharmacogenomics and drug safety lead to complex ethical discussions. Integrating computer based technology in the production and drug testing phase would improve R&D productivity.


### COMPANY PERFORMANCE FOR SELECTED CRITERIA

#### ECONOMIC


##### Corporate Governance




##### Marketing Practices



##### Customer Relationship Management




##### Research and Development




#### ENVIRONMENTAL


##### Climate Strategy




##### Environmental Reporting



##### Environmental Policy/Management System




##### Operational Eco-Efficiency




#### SOCIAL


##### Human Capital Development




##### Standards for Suppliers



##### Labor Practice Indicators



##### Talent Attraction & Retention



- DJSI sector average on a global basis
- Roche Holding AG
- Best company on a global basis within DJSI sector

Contact  
SAM Research AG  
Josefstrasse 218  
CH-8005 Zurich · Switzerland  
Tel. +41 44 653 10 10  
Fax +41 44 653 10 50  
[info@sam-group.com](mailto:info@sam-group.com)  
[www.sam-group.com](http://www.sam-group.com)



#### DISCLAIMER

No offer. The information and opinions contained in this publication constitutes neither a solicitation, nor a recommendation, nor an offer to buy or sell investment instruments or other services, or to engage in any other kind of transaction. The information described in this publication is not directed to persons in any jurisdiction where the provision of such information would run counter to local laws and regulation. No warranty. This publication is derived from sources believed to be accurate and reliable, but neither its accuracy nor completeness is guaranteed. The material and information in this publication are provided "as is" and without warranties of any kind, either expressed or implied. SAM Group Holding AG and its related, affiliated and subsidiary companies disclaim all warranties, expressed or implied, including, but not limited to, implied warranties of merchantability and fitness for a particular purpose. Any opinions and views in this publication reflect the current judgment of the authors and may change without notice. It is each reader's responsibility to evaluate the accuracy, completeness and usefulness of any opinions, advice, services or other information provided in this publication. Limitation of liability All information contained in this publication is distributed with the understanding that the authors, publishers and distributors are not rendering legal, accounting or other professional advice or opinions on specific facts or matters and accordingly assume no liability whatsoever in connection with its use. In no event shall SAM Group Holding AG and its related, affiliated and subsidiary companies be liable for any direct, indirect, special, incidental or consequential damages arising out of the use of any opinion or information expressly or implicitly contained in this publication. Copyright Unless otherwise noted, text, images and layout of this publication are the exclusive property of SAM Group Holding AG and/or its related, affiliated and subsidiary companies and may not be copied or distributed, in whole or in part, without the express written consent of SAM Group AG or its related, affiliated and subsidiary companies.